Seak Therapeutics, LLC
Memphis, TN
- UEI
- HBTSD5J8NL84
- CAGE
- 87ZA7
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Sole Proprietorship
- SAM.gov registration date
- Physical address
- 881 Madison Ave #561, Memphis, TN 38163, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis… | National Cancer Institute | $399,981 | |
| Developing a selective TRPC3 ION channel inhibitor for epilepsy treatment - project summary epilepsy is one of the… | National Institute of Neurological Disorders and Stroke | $429,932 | |
| Feasibility study of developing seak-114 for the treatment of pediatric cancers | National Cancer Institute | $399,964 | |
| Development of a dual MDM2/xiap inhibitor with a high therapeutic index for childhood cancers | National Cancer Institute | $354,823 |
About Seak Therapeutics, LLC
Seak Therapeutics, LLC is a for-profit, limited liability company and sole proprietorship registered to receive federal grants and contracts. Based on its name, it appears to be a biotechnology or pharmaceutical company focused on developing therapeutic drugs and treatments.
Seak Therapeutics has received several grants from the National Institutes of Health (NIH) to fund drug development research projects. In 2023, it was awarded a $429,932 grant from the NIH's National Institute of Neurological Disorders and Stroke to develop a selective inhibitor of the TRPC3 ion channel called JW-65 as a potential treatment for epilepsy. The project involves comprehensive evaluation of JW-65's safety, pharmacokinetics, and efficacy in suppressing acute seizures in rodent models. Earlier, in 2020, Seak received two grants totaling $754,787 from the NIH's National Cancer Institute. One grant for $399,964 aimed to study the feasibility of developing SEAK-114 for treating pediatric cancers. The other $354,823 grant supported the development of a dual MDM2/XIAP inhibitor with a high therapeutic index for childhood cancers. Seak Therapeutics appears to specialize in early-stage drug discovery and preclinical development, particularly for neurological disorders and cancers, by leveraging federal funding from the NIH.
Quick answers
What is Seak Therapeutics, LLC's UEI?
Seak Therapeutics, LLC's Unique Entity ID (UEI) in SAM.gov is HBTSD5J8NL84.
What is Seak Therapeutics, LLC's CAGE code?
Seak Therapeutics, LLC's CAGE code is 87ZA7.
Where is Seak Therapeutics, LLC located?
Seak Therapeutics, LLC's physical address in SAM.gov is 881 Madison Ave #561, Memphis, TN 38163, USA.
Is Seak Therapeutics, LLC registered in SAM.gov?
Yes. Seak Therapeutics, LLC's SAM.gov registration is active through August 16, 2027.
What is Seak Therapeutics, LLC's most recent federal award?
Seak Therapeutics, LLC's most recent federal grant award is Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis… (R41CA310186), from National Cancer Institute, on September 19, 2025.
On GovTribe
See Seak Therapeutics, LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors